---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-24-000054"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:06:02.214186+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q1 net loss $31.9M; FDA grants Priority Review for HAV, PDUFA Aug 10, 2024

## Summary
- Net loss $31.9M vs $37.0M YoY; no revenue; cash $115.5M, up from $35.1M net provided.
- BLA for HAV in vascular trauma accepted with Priority Review; PDUFA date Aug 10, 2024.
- Raised ~$43M net from public offering in March 2024; additional $20M draw from Oberland facility.
- Total operating expenses $26.6M flat QoQ; R&D $21.3M up from $17.3M YoY.
- Preparations for US launch ongoing: hired VP Sales, completed Budget Impact Model, seeking ICD-10 code.

## SEC filing metadata
- accession: 0001818382-24-000054
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/0001818382-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/huma-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-24-000054
- JSON: https://secwatch.observer/filing/0001818382-24-000054.json
- Plain text: https://secwatch.observer/filing/0001818382-24-000054.txt

## Key facts
- Earnings Releases
  Humacyte, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 10, 2024, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/0001818382-24-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.